Earnings summaries and quarterly performance for AURORA CANNABIS.
Research analysts who have asked questions during AURORA CANNABIS earnings calls.
Pablo Zuanic
Zuanic & Associates
5 questions for ACB
Also covers: AFCG, CGC, CRLBF +15 more
DL
Derek Lessard
TD Cowen
4 questions for ACB
Also covers: PRMB, PRMW
BK
Bill Kirk
Roth Capital Partners, LLC
3 questions for ACB
Also covers: CGC, CRON, GO +8 more
BC
Brenna Cunnington
ATB Capital Markets
2 questions for ACB
Also covers: CGC, HITI, OGI +1 more
FG
Frederico Gomes
ATB Capital Markets
2 questions for ACB
Also covers: AAWH, AYRWF, CGC +9 more
KT
Kenric Tyghe
ATB Capital Markets
2 questions for ACB
Also covers: AAWH, AYRWF, JUSHF +3 more
MB
Matt Bottomley
Canaccord Genuity Group Inc.
2 questions for ACB
Also covers: AYRWF, CGC, CURLF +7 more
DM
Douglas Miehm
RBC Capital Markets
1 question for ACB
Also covers: AUPH, BHC, BLCO +2 more
Tamy Chen
BMO Capital Markets
1 question for ACB
Also covers: MGA
WK
William Kirk
ROTH MKM
1 question for ACB
Also covers: ACI, CGC, CURLF +10 more
Recent press releases and 8-K filings for ACB.
Aurora Cannabis Emphasizes Medical Cannabis Strategy and International Growth
ACB
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Aurora Cannabis has completed a multi-year restructuring, resulting in debt-free cannabis operations and a strong net cash position. The company has strategically pivoted to focus primarily on the higher-margin medical cannabis business, divesting its plant propagation business and scaling back its lower-margin consumer segment.
- This strategic shift has driven record revenue and Adjusted EBITDA growth, with global medical cannabis revenue reaching CAD 212 million year-to-date compared to CAD 177 million last year, and achieving mid-to-high 60s% margins in the medical segment.
- The company is expanding its international presence, notably doubling production capacity in its German manufacturing facility and holding a leading position in markets like Poland, targeting an estimated CAD 9 billion addressable market in medical cannabis, particularly in Europe and Australia.
- Aurora maintains a strong balance sheet and has established an ATM up to $100 million for strategic, accretive uses such as capacity expansion or M&A, while providing an updated full-year outlook reflecting strong growth despite regulatory uncertainties.
1 day ago
Aurora Cannabis Prioritizes Medical Cannabis and International Markets for Profitable Growth
ACB
New Projects/Investments
Revenue Acceleration/Inflection
M&A
- Aurora Cannabis has strategically pivoted to focus primarily on the higher-margin medical cannabis business and high-growth international markets, divesting its plant propagation business and scaling back its consumer segment.
- The company has delivered record revenue and adjusted EBITDA growth, generated free cash flow, and strengthened its balance sheet. Global medical cannabis revenue on a year-to-date basis is CAD 212 million, reflecting strong growth from these markets.
- Aurora emphasizes its competitive advantages in GMP manufacturing capabilities in Canada and Germany, operational excellence, commercial execution, and regulatory expertise, positioning it as a leader in key international markets like Germany and Poland.
- The estimated addressable market for international medical cannabis is over CAD 9 billion, presenting significant growth opportunities for the company, particularly in Europe and Australia.
1 day ago
Aurora Cannabis Shifts Focus to High-Margin Medical Cannabis Business, Reports Strong Growth
ACB
New Projects/Investments
Revenue Acceleration/Inflection
M&A
- Aurora Cannabis has completed a multi-year restructuring, achieving debt-free cannabis operations and a strong net cash position.
- The company has strategically pivoted to focus primarily on the higher-margin medical cannabis business, divesting its plant propagation business and scaling back its lower-margin consumer segment to concentrate investments.
- The medical cannabis segment is the company's growth engine, reporting CAD 212 million in global medical cannabis revenue year-to-date (compared to CAD 177 million last year) and targeting an estimated addressable market of over CAD 9 billion.
- Aurora leverages its GMP manufacturing capabilities, operational efficiencies, and regulatory expertise to maintain mid-to-high 60s% margins and support its leadership position in markets like Germany and Poland. The company has also established an ATM for up to $100 million for strategic, accretive M&A opportunities.
1 day ago
Aurora Cannabis Inc. Announces US$100 Million Share Offering
ACB
- Aurora Cannabis Inc. (ACB) has entered into an agreement with TD Securities (USA) LLC to issue and sell common shares with an aggregate offering price of up to US$100,000,000.
- This offering is part of a broader Canadian base shelf prospectus, dated February 14, 2025, which allows for the issuance of up to US$250,000,000 of various securities, including common shares.
- The company's common shares are listed on the TSX and Nasdaq, and the Placement Shares from this offering will also be listed on these exchanges.
- Aurora Cannabis Inc. and its subsidiaries confirm compliance with applicable Canadian and U.S. securities laws, as well as holding all necessary Cannabis Licenses and German Licenses.
Feb 4, 2026, 9:44 PM
Aurora Cannabis Announces At-The-Market Offering Program
ACB
New Projects/Investments
M&A
- Aurora Cannabis Inc. has filed a prospectus supplement to establish a new At-The-Market (ATM) Offering Program.
- The program allows the company to issue and sell up to U.S.$100 million of common shares from treasury.
- The net proceeds from the offering are intended for strategic and accretive purposes, including increased cultivation capacity and M&A.
- Sales will be made through the NASDAQ Capital Market or other marketplaces in the United States at prevailing market prices, with no sales occurring in Canada.
Feb 4, 2026, 2:45 PM
Aurora Cannabis Reports Strong Q3 2026 Results and Strategic Focus on Global Medical Cannabis
ACB
Earnings
Guidance Update
M&A
- Aurora Cannabis reported strong financial results for Q3 2026, with net revenue increasing 7% to CAD 94.2 million, adjusted gross margin rising 100 basis points to 62%, CAD 18.5 million in adjusted EBITDA, and CAD 15.5 million in positive free cash flow.
- The company is strategically reallocating resources to prioritize the global medical cannabis market, which saw 12% revenue growth in Q3 2026, by exiting select Canadian consumer cannabis markets and divesting its controlling stake in the lower-margin Bevo plant propagation business.
- For fiscal year 2026, annual global medical cannabis net revenue is projected to increase year-over-year to between CAD 269 million and CAD 281 million, driven by 10%-15% growth in the segment.
- An At-the-Market (ATM) equity program has been established, allowing the company to issue and sell up to $100 million of common shares for strategic and accretive purposes, including increased cultivation capacity and potential M&A.
Feb 4, 2026, 1:00 PM
Aurora Cannabis Reports Strong Q3 2026 Results and Strategic Focus on Medical Cannabis
ACB
Earnings
Guidance Update
New Projects/Investments
- Aurora Cannabis (ACB) reported Q3 2026 net revenue of CAD 94.2 million, a 7% increase, primarily driven by 12% growth in global medical cannabis revenue.
- The company achieved adjusted EBITDA of CAD 18.5 million, adjusted net income of CAD 7.2 million, and positive free cash flow of CAD 15.5 million in Q3 2026.
- Strategic actions include exiting select Canadian consumer cannabis markets and divesting its plant propagation operations (Bevo) to focus on higher-margin global medical cannabis, alongside establishing an At-the-Market (ATM) equity program for up to $100 million in common shares.
- For fiscal year 2026, Aurora anticipates annual global medical cannabis net revenue between CAD 269 million and CAD 281 million and annual consolidated Adjusted EBITDA between CAD 52 million and CAD 57 million.
Feb 4, 2026, 1:00 PM
Aurora Cannabis Reports Strong Q3 2026 Results and Announces Strategic Reallocation
ACB
Earnings
Guidance Update
New Projects/Investments
- Aurora Cannabis reported strong Q3 2026 financial results, with net revenue increasing 7% to CAD 94.2 million and global medical cannabis revenue growing 12% to CAD 76.2 million. The company achieved an adjusted gross margin of 62% and adjusted EBITDA of CAD 18.5 million, along with positive free cash flow of CAD 15.5 million.
- The company is strategically reallocating resources to focus on the higher-margin global medical cannabis market, which involves exiting select Canadian consumer cannabis segments and divesting its controlling stake in the plant propagation business (Bevo). These actions are expected to improve operational efficiency and profitability.
- Aurora maintains a strong balance sheet with CAD 154 million in cash and no cannabis business-related debt. It also established an At-the-Market (ATM) equity program to issue up to $100 million in common shares for strategic purposes, including increased cultivation capacity and potential M&A.
- For fiscal year 2026, the company expects annual global medical cannabis net revenue between CAD 269 million and CAD 281 million, and annual consolidated Adjusted EBITDA in the range of CAD 52 million-CAD 57 million, representing 5%-10% annual growth.
Feb 4, 2026, 1:00 PM
Aurora Cannabis Reports Q3 2026 Financial Results
ACB
Earnings
Financial Restatement
New Projects/Investments
- For the three months ended December 31, 2025, Aurora Cannabis Inc. reported net revenue of $94,191 thousand, an increase from $88,198 thousand in the prior year period, but recorded a net loss of $1,903 thousand compared to a net income of $28,225 thousand in the same period last year.
- Adjusted EBITDA for the three months ended December 31, 2025, was $18,479 thousand, a slight decrease from $19,393 thousand in the prior year period. Working capital as of December 31, 2025, stood at $299,901 thousand, down from $338,741 thousand as of December 31, 2024.
- The company filed a prospectus supplement for a new at-the-market equity program allowing it to issue and sell up to U.S. $100 million of common shares for strategic and accretive purposes. Additionally, Bevo Agtech Inc., a controlled interest, was not in compliance with a financial covenant under its credit agreement and is in discussions with its lender.
Feb 4, 2026, 12:05 PM
Aurora Cannabis Announces ATM Offering Program
ACB
New Projects/Investments
M&A
- Aurora Cannabis Inc. has established a new at-the-market (ATM) offering program.
- This program allows the company to issue and sell up to U.S.$100 million of common shares.
- The net proceeds from the offering are intended for strategic and accretive purposes, including increased cultivation capacity and M&A.
- Sales will be made through the NASDAQ Capital Market or another marketplace in the United States at prevailing market prices.
Feb 4, 2026, 12:00 PM
Quarterly earnings call transcripts for AURORA CANNABIS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more